Main > > >PANCREAS CANCER. *

NeuroEndocrine Tumors (NATs.)>Gastro- EntericPancreatic (GEP) NET. Treat.: 177Lu-Edotreotide.
UnResectable.
Status: Phase III.
Companion Diagnostics>
68Ga-Edotreotide>AT,DE,FR Approval
Date: 2018. 05.25.
Lutetium-177>EU Approval Date: 2016.
08.04.
(*) Company; Patents; TradeMarks & Web-
Sites Available on Request.
UpDate: 2018. 11.24.




NeuroEndocrine Tumors (NETs.)>Gastro- EntericPancreatic (GEP) NET. Treat.: 177Lu-OxodoTreotide.
[Somatostatin Receptor (SR)+].
>Companion Diagnostics>
68Ga OxodoTreotide>Approved in EU, USA
EU Approval Date : 2017. 09.29.
USA Approval Date: 2018. 01.26.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.25.




NeuroEndocrine Tumors (NETs.)>Gastro-EntericPancreatic (GEP) NET. Treat.: Lanreotide Acetate Inj.
(Metastatic; NonResectable)
JP Approval Date : 2017. 07.03.
USA Approval Date: 2014. 12.16.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 11.25.




NeuroEndocrine Tumors (NETs.)>Pancreatic NET. Treat.: Everolimus Tablets.>UnRe- sectable.
EU Approval Date : 2011. 09.05.
USA Approval Date: 2011. 05.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.23.




Onco.>RadioTherapy>BrachyTherapy>Low Ra-
te Dose (LRD) BrachyTherapy.
>Indications Potential>
>atypical meningioma
>non-small-cell lung cancer
>ocular melanoma
>Indications Used>
>colorectal cancer
>gynecological cancer
>head and neck cancer
>pancreatic cancer
>soft tissue sarcomas
USA Approval Date: 2014. 08.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.25.




TREAT.: Erlotinib.HCl Tab.+Gemcitabine.
Brand.
Metastatic; UnResectable & Not Received
previous CT.
EU Approval Date : 2007. 01.29.
USA Approval Date: 2005. 11.
(*) Company : Astellas Pharma
Marketing EU : Roche.
Marketing USA: Astellas Pharma
Genentech.
Patent : Expired.
TradeMark : Tarceva.
Web-Site : www.tarceva.com
UpDate: 2018. 12.10.




TREAT.: Erlotinib.HCl Tab.+Gemcitabine.
Generic.
Metastatic; UnResectable & Not Received
previous CT.
USA Launch Date: 2019. 11.13.
(*) Company: Armas Pharmaceuticals.
UpDate: 2019. 11.14.




TREAT.: Erlotinib.HCl Tab.+Gemcitabine.
Generic.
Metastatic; UnResectable & Not Received
previous CT.
USA Final Approval Date: 2019. 11.12.
(*) Company: Breckenridge Pharma. Inc.
UpDate: 2019. 11.18.




TREAT.: Erlotinib.HCl Tab.+Gemcitabine.
Generic.
Metastatic; UnResectable & Not Received
previous CT.
USA Launch Date: 2019. 05.10.
(*) Company: Mylan.
UpDate: 2020. 01.02.




TREAT.: Gemcitabine.HCl Inj. for IV Use
USA 1st Approval Year: 1996.
(*) Company : Eli Lilly.
Patent : Expired
TradeMark: Gemzar.
Web-Site :
pi.lilly.com/us/gemzar.pdf
UpDate: 2018. 12.10.




TREAT.: Irinotecan Liposome Inj.+>
(METASTATIC)
+FluoroUracil+Leucovorin.
>disease progression following Gemci-
tabine-based therapy.
CA Approval Date : 2017. 08.11.
EU Approval Date : 2016. 10.18.
USA Approval Date: 2015. 10.22.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.10.




TREAT.: Mitomycin for Inj. Generic.
(METASTATIC)
USA Launch Date: 2018. 03.20.
(*) Company: Mylan.
UpDate: 2018. 12.10.




TREAT.: Olaparib Tablets.
[METASTATIC>germline BRCA-mutated
(gBRCAm)]>Whose Disease has NOT Progre-
ssed on > 16 weeks of 1st Line Pt
ChemoTherapy.
Companion Diagnostics>
>USA Approval Date: 2019. 12.30.
PARP Inhibitor.
EU Approval Date : 2020. 07.08.
JP Approval Date : 2020. 12.28.
USA Approval Date : 2019. 12.30.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2021. 02.10.




TREAT.: Paclitaxel Albumin Particles
for Injectable Suspension.+
(METASTATIC)
+Gemcitabine.
USA Approval Date: 2013. 09.06.
(*) Company : Celgene.
TradeMark: Abraxane
Web-Site : www.abraxane.com
UpDate: 2018. 12.10.




TREAT.: PembrolizuMAb Inj.
[METASTATIC; MicroSatellite Instability-
High (MSI-H)].
USA Approval Date: 2017. 05.23.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 12.10.




TREAT.: Tertomotide HCl Inj.>
(METASTATIC)
>Eotaxin Level in Serum>81.02pg/mL
KR Approval Date: 2015. 09.15.
(*) Company : GemVax & KAEL Co. Ltd.
TradeMark: RIAVAX
Web-Site :
www.gemvax.com/en/product/index.jsp
UpDate: 2018. 12.10.


>PANCREAS CANCER. *'s products
This section has no products